Quality of care in diabetes: understanding the guidelines.
We are in the midst of a global pandemic of diabetes. Despite the increasing burden of the disease, measurements of quality repeatedly show poor adherence to or implementation of current guidelines for diabetes care. This article will provide a brief review of the most significant randomized controlled clinical trials relevant to the current guidelines and then discuss essential treatment goals and the evidence that supports them. Several practical clinical questions related to the implementation of modern diabetes guidelines will be raised and answered. Finally, reasons for the poor quality performance observed will be examined.
Bouldin
Marshall J
MJ
Department of Medicine, University of Mississippi Medical Center, Jackson 39216-4505, USA. mbouldin@medicine.umsmed.edu
Low
Annette K
AK
Blackston
Joseph W
JW
Duddleston
David N
DN
Holman
Honey E
HE
Hicks
G Swink
GS
Brown
C Andrew
CA
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000628:therapy*; D017408:Guidelines as Topic; D006801:Humans; D007668:Kidney / Q000473:pathology; D050356:Lipid Metabolism; D011787:Quality of Health Care; D016032:Randomized Controlled Trials as Topic; D012160:Retina / Q000473:pathology; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001786:Blood Glucose; D001241:Aspirin